Modeling Pharmacokinetic Profiles for Assessment of Anti-Cancer Drug on a Microfluidic System

被引:8
|
作者
Guo, Yaqiong [1 ,2 ]
Deng, Pengwei [1 ,2 ]
Chen, Wenwen [1 ,2 ]
Li, Zhongyu [1 ,3 ]
机构
[1] Chinese Acad Sci, Dalian Inst Chem Phys, Div Biotechnol, CAS Key Lab Separat Sci Analyt Chem, Dalian 116023, Peoples R China
[2] Univ Chinese Acad Sci, Beijing 100190, Peoples R China
[3] Dalian Minzu Univ, Coll Life Sci, Dalian 116600, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
microfluidics; intestine; drug; pharmacokinetic (PK) profile; CHIP; METABOLISM; ORGANS; TOXICITY; PLATFORM; TISSUES; CELLS;
D O I
10.3390/mi11060551
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The pharmacokinetic (PK) properties of drug, which include drug absorption and excretion, play an important role in determining the in vivo pharmaceutical activity. However, current in vitro systems that model PK profiles are often limited by the in vivo-like concentration profile of a drug. Herein, we present a perfused and multi-layered microfluidic chip system to model the PK profile of anti-cancer drug 5-FU in vitro. The chip device contains two layers of culture channels sandwiched by a porous membrane, which allows for drug exposure and diffusion between the two channels. The integration of upper intestine cells (Caco-2) and bottom targeted cells within the device enables the generation of loading and clearance portions of a PK curve under peristaltic flow. Fluorescein as a test molecule was initially used to generate a concentration-time curve, investigating the effects of parameters of flow rate, administration time, and initial concentration on dynamic drug concentration profiles. Furthermore, anti-cancer drug 5-FU was performed to assess its pharmaceutical activity on target cells (human lung adenocarcinoma cells or human pulmonary alveolar epithelial cells) using different drug administration regimens. A dynamic, in vivo-like 5-FU exposure refers to PK profile regimen, led to generate a lower drug concentration (dynamically fluctuate from 0 to 1 mu g/mL affected by absorption) compared to the constant exposure. Moreover, the PK profile regimen alleviates the drug-induced cytotoxicity on target cells. These results demonstrate the feasibility of determining the PK profiles using this microfluidic system with in vivo-like drug administration regimens. This established system may provide a powerful platform for the prediction of drug safety and effectiveness in the pharmaceutical research.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Quantitative impedimetric monitoring of cell migration under the stimulation of cytokine or anti-cancer drug in a microfluidic chip
    Liu, Lu
    Xiao, Xia
    Lei, Kin Fong
    Huang, Chia-Hao
    BIOMICROFLUIDICS, 2015, 9 (03):
  • [42] Anti-cancer drug sensitivity in sinonasal squamous cancer
    Garcia-Inclan, Cristina
    Lopez, Fernando
    Potes-Ares, Sira
    Llorente, Jose L.
    Hermsen, Mario
    CELLULAR ONCOLOGY, 2012, 35 : S46 - S46
  • [43] PEG based anti-cancer drug conjugated prodrug micelles for the delivery of anti-cancer agents
    Senevirathne, Suchithra A.
    Washington, Katherine E.
    Biewer, Michael C.
    Stefan, Mihaela C.
    JOURNAL OF MATERIALS CHEMISTRY B, 2016, 4 (03) : 360 - 370
  • [44] Microfluidic fabrication of cationic curcumin nanoparticles as an anti-cancer agent
    Dev, Selvi
    Prabhakaran, Praseetha
    Filgueira, Luis
    Iyer, K. Swaminathan
    Raston, Colin L.
    NANOSCALE, 2012, 4 (08) : 2575 - 2579
  • [45] Microbioassay System for an Anti-cancer Agent Test Using Animal Cells on a Microfluidic Gradient Mixer
    Shin-ichiro Fujii
    Munehisa Uematsu
    Soichi Yabuki
    Mitsuru Abo
    Etsuro Yoshimura
    Kiichi Sato
    Analytical Sciences, 2006, 22 : 87 - 90
  • [46] Microbioassay system for an anti-cancer agent test using animal cells on a microfluidic gradient mixer
    Fujii, S
    Uematsu, M
    Yabuki, S
    Abo, M
    Yoshimura, E
    Sato, K
    ANALYTICAL SCIENCES, 2006, 22 (01) : 87 - 90
  • [47] ψ-Bufarenogin, a lead compound of anti-cancer drug
    Ding, Jin
    Wang, Hongyang
    CELL CYCLE, 2015, 14 (17) : 2719 - 2720
  • [48] PET in anti-cancer drug development and therapy
    Kumar, Rakesh
    Lal, Neena
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2007, 2 (03) : 259 - 263
  • [49] NEW APPROACH TO ANTI-CANCER DRUG DEVELOPMENT
    LANDES, RC
    BRITISH JOURNAL OF CANCER, 1975, 31 (02) : 254 - 254
  • [50] Development of Nanostructured Liquid Crystalline Formulation of Anti-Cancer Drug as a New Drug Delivery System
    El-Enin, Hadel A. Abo
    JOURNAL OF PHARMACEUTICAL INNOVATION, 2020, 15 (01) : 80 - 93